Compare Incyte Corporation (INCY) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Annaly Capital Management, Inc. — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Annaly Capital Management, Inc. trades at $23.3 (market cap $17.44B). The key difference: Incyte Corporation is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 12.96% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NLY | |
|---|---|---|
Market Cap | $24.54B | $17.44B |
Sector | Health | Financials |
52-Week High | $129.93 | $24.40 |
52-Week Low | $81.61 | $20.21 |
Enterprise Value | $20.04B | — |
Dividend Yield | — | 12.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
NLY trades at $23.28, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.59 and a high ROE of 20.66%. Recent quarterly earnings have consistently beaten estimates, and the company maintains a significant dividend yield. Analyst consensus is positive, with a $24.50 price target, supported by recent upgrades and institutional buying activity.
The outlook for NLY is favorable, driven by earnings growth and a high dividend yield, but risks include interest rate sensitivity and high leverage. The stock offers value and income appeal, yet investors should weigh the cyclical nature of the mortgage REIT sector against the strong analyst support and recent financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
